Topical Bimatoprost in the Treatment of Migraine

• Status: Unknown status
• Trial end date: 2019-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The study is to assess the effectiveness of topically applied bimatoprost in reducing migraine headache frequency, severity, and duration. It will also assess the effect of topical bimatoprost on quality of life.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Manistee Partners
• Treatments: Bimatoprost; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Diagnosis of migraines based on International Classification of Headache Disorders (ICHD) II criteria and experiencing headaches for 4 or more days per month.

Exclusion Criteria:

• Significant liver or renal dysfunction,

• On treatment for inflammatory bowel disease, medication over-use for headaches according to the ICHD II criteria,

• Use of antipsychotics in the past month,

• Recent (in the past six months) history of alcohol or drug abuse,

• Allergy to bimatoprost and its compounds,

• Severe comorbid psychiatric illness,

• Severe infection,

• Malignancy,

• Severe cardiovascular disease,

• Neurodegenerative disorders,

• Pregnancy and lactation, and

• Sexually active women of child bearing age who do not use any method of contraception.